Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H35Cl2N3O2 |
| Molecular Weight | 552.535 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C2=CC=CC=C2)C3=CC=C(Cl)C(Cl)=C3)C(=O)C4=CC=CC=C4
InChI
InChIKey=PGKXDIMONUAMFR-AREMUKBSSA-N
InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1
| Molecular Formula | C31H35Cl2N3O2 |
| Molecular Weight | 552.535 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sanofi aventis developed saredutant (also known as SR 48968C) as a tachykinin neurokinin-2 (NK2) receptor antagonist for the treatment of depressive disorders and generalized anxiety disorder. This drug participated in phase III clinical trials in patients with a generalized anxiety disorder and as Combination Treatment for major depressive disorder, however, the drug failed to meet efficacy endpoints. It is known that NK-2 receptor mediates airway obstruction that is why saredutant was studied as a potential treatment of asthma. However, all studies of the drug were discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery. | 2010-11-26 |
|
| ACS chemical neuroscience molecule spotlight on Saredutant. | 2010-10-20 |
|
| Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights. | 2010-09-20 |
|
| Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. | 2010-08 |
|
| Contractile responses induced by physalaemin, an analogue of substance P, in the rat esophagus. | 2010-02-25 |
|
| Involvement of sensory nerves and TRPV1 receptors in the rat airway inflammatory response to two environment pollutants: diesel exhaust particles (DEP) and 1,2-naphthoquinone (1,2-NQ). | 2010-02 |
|
| Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. | 2009-05-01 |
|
| Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor. | 2009-05 |
|
| Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. | 2008-09 |
|
| Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants. | 2008-08-15 |
|
| Capsaicin-evoked bradycardia in anesthetized guinea pigs is mediated by endogenous tachykinins. | 2008-04-10 |
|
| Role of tachykinin NK(1) and NK(2) receptors in colonic sensitivity and stress-induced defecation in gerbils. | 2008-03-17 |
|
| Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. | 2008-03 |
|
| Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum. | 2007-11-06 |
|
| Role of capsaicin-sensitive afferents and sensory neuropeptides in endotoxin-induced airway inflammation and consequent bronchial hyperreactivity in the mouse. | 2007-06-07 |
|
| Tachykinin receptors antagonists: from research to clinic. | 2006-08 |
|
| Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. | 2006-04 |
|
| Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. | 2005-06-01 |
|
| Inducible nitric oxide synthase evoked nitric oxide counteracts capsaicin-induced airway smooth muscle contraction, but exacerbates plasma extravasation. | 2005-04-18 |
|
| Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. | 2005-01-10 |
|
| Targeting tachykinins for the treatment of obstructive airways disease. | 2004 |
|
| Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons. | 2003-08 |
|
| SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. | 2002-08-23 |
|
| Effect of a tachykinin NK(2) receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs. | 2001-03-09 |
|
| Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats. | 2000 |
|
| Effect of tachykinin receptor antagonists in experimental neuropathic pain. | 1998-11-20 |
|
| Acetylcholine and tachykinin receptor antagonists attenuate wood smoke-induced bronchoconstriction in guinea pigs. | 1998-11-06 |
|
| Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice. | 1997-08 |
|
| Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. | 1997-06 |
|
| Role of tachykinins in castor oil diarrhoea in rats. | 1997-06 |
|
| The non-peptide tachykinin NK1- and NK2-receptor antagonists SR 140333 and SR 48968 prevent castor-oil induced diarrhea in rats. | 1996 |
|
| The inhibitory modulation of guinea-pig intestinal peristalsis caused by capsaicin involves calcitonin gene-related peptide and nitric oxide. | 1995-12 |
|
| Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. | 1995-10 |
|
| Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? | 1995-06 |
|
| 'Sensory-efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. | 1994-12 |
|
| Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. | 1994-09 |
|
| Capsaicin-induced bladder hyperactivity in normal conscious rats. | 1994-08 |
|
| Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. | 1994-07-01 |
|
| Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder. | 1994-04 |
|
| The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors. | 1994-02-15 |
|
| Expression of rat NK-2 (neurokinin A) receptor in E. coli. | 1994 |
|
| Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor. | 1993-03-31 |
|
| Influence of (+/-)-CP-96,345 and SR 48968 on electrical field stimulation of the isolated guinea-pig main bronchus. | 1992-12-02 |
|
| A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. | 1992 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00417118
Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:55:21 GMT 2025
by
admin
on
Wed Apr 02 07:55:21 GMT 2025
|
| Record UNII |
720U2QK8I5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB10449MIG
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
7487
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
104974
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
142001-63-6
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
Saredutant
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
DTXSID00161923
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
100000084095
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
2111
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
DB06660
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
C152301
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
720U2QK8I5
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL308148
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Tachykinin NK2 receptor antagonist that was developed by Sanofi-Aventis for anti-depressant potential
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |